The Latest Breaking News from Terns Pharmaceuticals

This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%

Merck is beating the market year-to-date after a jump on positive Phase 3 data, while paying an annualized dividend of about $3.40 for a yield above 2.3%.

Barchart · Sep 16

Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated chronic myeloid leukemia (CML) patients at the American Society of Hematology Annual Meeting and Exposition.

Benzinga · Dec 9, 2025

5 Under-the-Radar Biotech Stocks That Could Soar in 2026

These smaller innovators are quietly advancing promising therapies that could unlock their true potential.

Barchart · Oct 28, 2025